Wall Street Buying Shire’s Rationale For Sluggish Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire remains on track for 2016 and 2020 sales targets, CEO says, as second quarter flatness was caused by foreign exchange impacts and generic competition to ADHD drug Intuniv.